Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 226


International Consensus Radiochemistry Nomenclature Guidelines.

Coenen HH, Gee AD, Adam M, Antoni G, Cutler CS, Fujibayashi Y, Jeong JM, Mach RH, Mindt TL, Pike VW, Windhorst AD.

Nuklearmedizin. 2018 Feb;57(1):40-41. doi: 10.1055/s-0038-1636563. Epub 2018 Feb 21. No abstract available.


Open letter to journal editors on: international consensus radiochemistry nomenclature guidelines.

Coenen HH, Gee AD, Adam M, Antoni G, Cutler CS, Fujibayashi Y, Jeong JM, Mach RH, Mindt TL, Pike VW, Windhorst AD.

Am J Nucl Med Mol Imaging. 2018 Feb 5;8(1):70-72. eCollection 2018. No abstract available.


Selectivity of probes for PET imaging of dopamine D3 receptors.

Doot RK, Dubroff JG, Labban KJ, Mach RH.

Neurosci Lett. 2018 Mar 5. pii: S0304-3940(18)30175-7. doi: 10.1016/j.neulet.2018.03.006. [Epub ahead of print] Review.


PET Imaging of Microglial Activation-Beyond Targeting TSPO.

Janssen B, Vugts DJ, Windhorst AD, Mach RH.

Molecules. 2018 Mar 8;23(3). pii: E607. doi: 10.3390/molecules23030607. Review.


A PET imaging agent for evaluating PARP-1 expression in ovarian cancer.

Makvandi M, Pantel A, Schwartz L, Schubert E, Xu K, Hsieh CJ, Hou C, Kim H, Weng CC, Winters H, Doot R, Farwell MD, Pryma DA, Greenberg RA, Mankoff DA, Simpkins F, Mach RH, Lin LL.

J Clin Invest. 2018 Mar 6. pii: 97992. doi: 10.1172/JCI97992. [Epub ahead of print]


Design, synthesis, and in vitro evaluation of quinolinyl analogues for α-synuclein aggregation.

Yue X, Dhavale DD, Li J, Luo Z, Liu J, Yang H, Mach RH, Kotzbauer PT, Tu Z.

Bioorg Med Chem Lett. 2018 Apr 1;28(6):1011-1019. doi: 10.1016/j.bmcl.2018.02.031. Epub 2018 Feb 16.


Synthesis and pharmacological evaluation of 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline derivatives as sigma-2 receptor ligands.

Sun YT, Wang GF, Yang YQ, Jin F, Wang Y, Xie XY, Mach RH, Huang YS.

Eur J Med Chem. 2018 Mar 10;147:227-237. doi: 10.1016/j.ejmech.2017.11.016. Epub 2017 Nov 9.


Open letter to journal editors on: International Consensus Radiochemistry Nomenclature Guidelines.

Coenen HH, Gee AD, Adam M, Antoni G, Cutler CS, Fujibayashi Y, Jeong JM, Mach RH, Mindt TL, Pike VW, Windhorst AD.

Nucl Med Commun. 2018 Mar;39(3):193-195. doi: 10.1097/MNM.0000000000000799. No abstract available.


Open letter to journal editors on: International Consensus Radiochemistry Nomenclature Guidelines.

Coenen HH, Gee AD, Adam M, Antoni G, Cutler CS, Fujibayashi Y, Jeong JM, Mach RH, Mindt TL, Pike VW, Windhorst AD.

Ann Nucl Med. 2018 Apr;32(3):236-238. doi: 10.1007/s12149-018-1238-z. Epub 2018 Feb 8. No abstract available.


Open letter to journal editors on: International Consensus Radiochemistry Nomenclature Guidelines.

Coenen HH, Gee AD, Adam M, Antoni G, Cutler CS, Fujibayashi Y, Jeong JM, Mach RH, Mindt TL, Pike VW, Windhorst AD.

J Labelled Comp Radiopharm. 2018 Jan 13. doi: 10.1002/jlcr.3604. [Epub ahead of print] No abstract available.


Copper Loading of Preformed Nanoparticles for PET-Imaging Applications.

Lu HD, Wang LZ, Wilson BK, McManus SA, Jumai'an J, Padakanti PK, Alavi A, Mach RH, Prud'homme RK.

ACS Appl Mater Interfaces. 2018 Jan 31;10(4):3191-3199. doi: 10.1021/acsami.7b07242. Epub 2018 Jan 17.


Inflammation and DNA damage: Probing pathways to cancer and neurodegeneration.

Makvandi M, Sellmyer MA, Mach RH.

Drug Discov Today Technol. 2017 Nov;25:37-43. doi: 10.1016/j.ddtec.2017.11.001. Epub 2017 Nov 22. Review.


Highly Selective Dopamine D3 Receptor Antagonists with Arylated Diazaspiro Alkane Cores.

Reilly SW, Griffin S, Taylor M, Sahlholm K, Weng CC, Xu K, Jacome DA, Luedtke RR, Mach RH.

J Med Chem. 2017 Dec 14;60(23):9905-9910. doi: 10.1021/acs.jmedchem.7b01248. Epub 2017 Nov 21.


Development of a Positron Emission Tomography Radiotracer for Imaging Elevated Levels of Superoxide in Neuroinflammation.

Hou C, Hsieh CJ, Li S, Lee H, Graham TJ, Xu K, Weng CC, Doot RK, Chu W, Chakraborty SK, Dugan LL, Mintun MA, Mach RH.

ACS Chem Neurosci. 2017 Dec 3. doi: 10.1021/acschemneuro.7b00385. [Epub ahead of print]


Consensus nomenclature rules for radiopharmaceutical chemistry - Setting the record straight.

Coenen HH, Gee AD, Adam M, Antoni G, Cutler CS, Fujibayashi Y, Jeong JM, Mach RH, Mindt TL, Pike VW, Windhorst AD.

Nucl Med Biol. 2017 Dec;55:v-xi. doi: 10.1016/j.nucmedbio.2017.09.004. Epub 2017 Oct 2. Review.


Challenges in the development of dopamine D2- and D3-selective radiotracers for PET imaging studies.

Mach RH, Luedtke RR.

J Labelled Comp Radiopharm. 2017 Aug 31. doi: 10.1002/jlcr.3558. [Epub ahead of print]


Small Molecule Receptor Ligands for PET Studies of the Central Nervous System-Focus on G Protein Coupled Receptors.

Mach RH.

Semin Nucl Med. 2017 Sep;47(5):524-535. doi: 10.1053/j.semnuclmed.2017.05.002. Epub 2017 Jul 6. Review.


Bacterial infection imaging with [18F]fluoropropyl-trimethoprim.

Sellmyer MA, Lee I, Hou C, Weng CC, Li S, Lieberman BP, Zeng C, Mankoff DA, Mach RH.

Proc Natl Acad Sci U S A. 2017 Aug 1;114(31):8372-8377. doi: 10.1073/pnas.1703109114. Epub 2017 Jul 17.


The role of beta-arrestin2 in shaping fMRI BOLD responses to dopaminergic stimulation.

Sahlholm K, Ielacqua GD, Xu J, Jones LA, Schlegel F, Mach RH, Rudin M, Schroeter A.

Psychopharmacology (Berl). 2017 Jul;234(13):2019-2030. doi: 10.1007/s00213-017-4609-6. Epub 2017 Apr 5.


Sigma-2 ligands and PARP inhibitors synergistically trigger cell death in breast cancer cells.

McDonald ES, Mankoff J, Makvandi M, Chu W, Chu Y, Mach RH, Zeng C.

Biochem Biophys Res Commun. 2017 May 6;486(3):788-795. doi: 10.1016/j.bbrc.2017.03.122. Epub 2017 Mar 24.


The Evolution of the Sigma-2 (σ2) Receptor from Obscure Binding Site to Bona Fide Therapeutic Target.

Zeng C, Mach RH.

Adv Exp Med Biol. 2017;964:49-61. doi: 10.1007/978-3-319-50174-1_5. Review.


[18F](2S,4R)4-Fluoroglutamine PET Detects Glutamine Pool Size Changes in Triple-Negative Breast Cancer in Response to Glutaminase Inhibition.

Zhou R, Pantel AR, Li S, Lieberman BP, Ploessl K, Choi H, Blankemeyer E, Lee H, Kung HF, Mach RH, Mankoff DA.

Cancer Res. 2017 Mar 15;77(6):1476-1484. doi: 10.1158/0008-5472.CAN-16-1945. Epub 2017 Feb 15.


Molecular Probes for Imaging the Sigma-2 Receptor: In Vitro and In Vivo Imaging Studies.

Zeng C, McDonald ES, Mach RH.

Handb Exp Pharmacol. 2017;244:309-330. doi: 10.1007/164_2016_96.


Design and Investigation of a [18F]-Labeled Benzamide Derivative as a High Affinity Dual Sigma Receptor Subtype Radioligand for Prostate Tumor Imaging.

Yang D, Comeau A, Bowen WD, Mach RH, Ross BD, Hong H, Van Dort ME.

Mol Pharm. 2017 Mar 6;14(3):770-780. doi: 10.1021/acs.molpharmaceut.6b01020. Epub 2017 Feb 14.


Quantitative PET Reporter Gene Imaging with [11C]Trimethoprim.

Sellmyer MA, Lee I, Hou C, Lieberman BP, Zeng C, Mankoff DA, Mach RH.

Mol Ther. 2017 Jan 4;25(1):120-126. doi: 10.1016/j.ymthe.2016.10.018. Epub 2017 Jan 4.


PARP-1 Expression Quantified by [18F]FluorThanatrace: A Biomarker of Response to PARP Inhibition Adjuvant to Radiation Therapy.

Sander Effron S, Makvandi M, Lin L, Xu K, Li S, Lee H, Hou C, Pryma DA, Koch C, Mach RH.

Cancer Biother Radiopharm. 2017 Feb;32(1):9-15. doi: 10.1089/cbr.2016.2133. Epub 2017 Jan 24.


A patient-derived-xenograft platform to study BRCA-deficient ovarian cancers.

George E, Kim H, Krepler C, Wenz B, Makvandi M, Tanyi JL, Brown E, Zhang R, Brafford P, Jean S, Mach RH, Lu Y, Mills GB, Herlyn M, Morgan M, Zhang X, Soslow R, Drapkin R, Johnson N, Zheng Y, Cotsarelis G, Nathanson KL, Simpkins F.

JCI Insight. 2017 Jan 12;2(1):e89760. doi: 10.1172/jci.insight.89760.


The Targeted SMAC Mimetic SW IV-134 is a strong enhancer of standard chemotherapy in pancreatic cancer.

Hashim YM, Vangveravong S, Sankpal NV, Binder PS, Liu J, Goedegebuure SP, Mach RH, Spitzer D, Hawkins WG.

J Exp Clin Cancer Res. 2017 Jan 17;36(1):14. doi: 10.1186/s13046-016-0470-4.


Absorbed radiation dosimetry of the D3-specific PET radioligand [18F]FluorTriopride estimated using rodent and nonhuman primate.

Laforest R, Karimi M, Moerlein SM, Xu J, Flores HP, Bognar C, Li A, Mach RH, Perlmutter JS, Tu Z.

Am J Nucl Med Mol Imaging. 2016 Nov 30;6(6):301-309. eCollection 2016.


PET of Poly (ADP-Ribose) Polymerase Activity in Cancer: Preclinical Assessment and First In-Human Studies.

Michel LS, Dyroff S, Brooks FJ, Spayd KJ, Lim S, Engle JT, Phillips S, Tan B, Wang-Gillam A, Bognar C, Chu W, Zhou D, Mach RH, Laforest R, Chen DL.

Radiology. 2017 Feb;282(2):453-463. doi: 10.1148/radiol.2016161929. Epub 2016 Nov 14.


Comparative evaluation of 4 and 6-carbon spacer conformationally flexible tetrahydroisoquinolinyl benzamide analogues for imaging the sigma-2 receptor status of solid tumors.

Lee I, Lieberman BP, Li S, Hou C, Makvandi M, Mach RH.

Nucl Med Biol. 2016 Nov;43(11):721-731. doi: 10.1016/j.nucmedbio.2016.08.001. Epub 2016 Aug 9.


Pd-Catalyzed Synthesis of Piperazine Scaffolds Under Aerobic and Solvent-Free Conditions.

Reilly SW, Mach RH.

Org Lett. 2016 Oct 13. [Epub ahead of print]


A systematic exploration of the effects of flexibility and basicity on sigma (σ) receptor binding in a series of substituted diamines.

Conroy T, Manohar M, Gong Y, Wilkinson SM, Webster M, Lieberman BP, Banister SD, Reekie TA, Mach RH, Rendina LM, Kassiou M.

Org Biomol Chem. 2016 Oct 4;14(39):9388-9405.


4-(((4-Iodophenyl)methyl)-4H-1,2,4-triazol-4-ylamino)-benzonitrile: A Potential Imaging Agent for Aromatase.

Song J, Wu Z, Wangtrakuldee B, Choi SR, Zha Z, Ploessl K, Mach RH, Kung H.

J Med Chem. 2016 Oct 27;59(20):9370-9380. Epub 2016 Oct 11.


Iodinated benzimidazole PARP radiotracer for evaluating PARP1/2 expression in vitro and in vivo.

Anderson RC, Makvandi M, Xu K, Lieberman BP, Zeng C, Pryma DA, Mach RH.

Nucl Med Biol. 2016 Dec;43(12):752-758. doi: 10.1016/j.nucmedbio.2016.08.007. Epub 2016 Aug 12.


4-aroylpiperidines and 4-(α-hydroxyphenyl)piperidines as selective sigma-1 receptor ligands: synthesis, preliminary pharmacological evaluation and computational studies.

Ikome HN, Ntie-Kang F, Ngemenya MN, Tu Z, Mach RH, Efange SM.

Chem Cent J. 2016 Aug 23;10(1):53. doi: 10.1186/s13065-016-0200-1. eCollection 2016.


The effect of the sigma-1 receptor selective compound LS-1-137 on the DOI-induced head twitch response in mice.

Malik M, Rangel-Barajas C, Mach RH, Luedtke RR.

Pharmacol Biochem Behav. 2016 Sep;148:136-44. doi: 10.1016/j.pbb.2016.07.001. Epub 2016 Jul 8.


A Radiotracer Strategy to Quantify PARP-1 Expression In Vivo Provides a Biomarker That Can Enable Patient Selection for PARP Inhibitor Therapy.

Makvandi M, Xu K, Lieberman BP, Anderson RC, Effron SS, Winters HD, Zeng C, McDonald ES, Pryma DA, Greenberg RA, Mach RH.

Cancer Res. 2016 Aug 1;76(15):4516-24. doi: 10.1158/0008-5472.CAN-16-0416. Epub 2016 Jun 3.


Conjugation to the sigma-2 ligand SV119 overcomes uptake blockade and converts dm-Erastin into a potent pancreatic cancer therapeutic.

Ohman KA, Hashim YM, Vangveravong S, Nywening TM, Cullinan DR, Goedegebuure SP, Liu J, Van Tine BA, Tiriac H, Tuveson DA, DeNardo DG, Spitzer D, Mach RH, Hawkins WG.

Oncotarget. 2016 Jun 7;7(23):33529-41. doi: 10.18632/oncotarget.9551.


PET imaging of in vivo caspase-3/7 activity following myocardial ischemia-reperfusion injury with the radiolabeled isatin sulfonamide analogue [(18)F]WC-4-116.

Thukkani AK, Shoghi KI, Zhou D, Xu J, Chu W, Novak E, Chen DL, Gropler RJ, Mach RH.

Am J Nucl Med Mol Imaging. 2016 Apr 24;6(2):110-9. eCollection 2016.


[(18)F]FluorThanatrace uptake as a marker of PARP1 expression and activity in breast cancer.

Edmonds CE, Makvandi M, Lieberman BP, Xu K, Zeng C, Li S, Hou C, Lee H, Greenberg RA, Mankoff DA, Mach RH.

Am J Nucl Med Mol Imaging. 2016 Jan 28;6(1):94-101. eCollection 2016.


Facile purification and click labeling with 2-[18F]fluoroethyl azide using solid phase extraction cartridges.

Zhou D, Chu W, Peng X, McConathy J, Mach RH, Katzenellenbogen JA.

Tetrahedron Lett. 2015 Feb 7;56(7):952-954. Epub 2014 Nov 4.


Improved Automated Radiosynthesis of [(11)C]PBR28.

Solingapuram Sai KK, Gage D, Nader M, Mach RH, Mintz A.

Sci Pharm. 2015 Jun 19;83(3):413-27. doi: 10.3797/scipharm.1505-06. Print 2015 Jul-Sep.


Novel Strategies for Breast Cancer Imaging: New Imaging Agents to Guide Treatment.

McDonald ES, Mankoff DA, Mach RH.

J Nucl Med. 2016 Feb;57 Suppl 1:69S-74S. doi: 10.2967/jnumed.115.157925. Review.


The pre-clinical characterization of an alpha-emitting sigma-2 receptor targeted radiotherapeutic.

Makvandi M, Lieberman BP, LeGeyt B, Hou C, Mankoff DA, Mach RH, Pryma DA.

Nucl Med Biol. 2016 Jan;43(1):35-41. doi: 10.1016/j.nucmedbio.2015.10.001. Epub 2015 Oct 22.


The sigma-2 receptor as a therapeutic target for drug delivery in triple negative breast cancer.

Makvandi M, Tilahun ED, Lieberman BP, Anderson RC, Zeng C, Xu K, Hou C, McDonald ES, Pryma DA, Mach RH.

Biochem Biophys Res Commun. 2015 Nov 27;467(4):1070-5. doi: 10.1016/j.bbrc.2015.09.157. Epub 2015 Oct 9.


The PGRMC1 Protein Level Correlates with the Binding Activity of a Sigma-2 Fluorescent Probe (SW120) in Rat Brain Cells.

Zeng C, Garg N, Mach RH.

Mol Imaging Biol. 2016 Apr;18(2):172-9. doi: 10.1007/s11307-015-0891-z.


Bitropic D3 Dopamine Receptor Selective Compounds as Potential Antipsychotics.

Luedtke RR, Rangel-Barajas C, Malik M, Reichert DE, Mach RH.

Curr Pharm Des. 2015;21(26):3700-24. Review.


Design, Synthesis, and Characterization of 3-(Benzylidene)indolin-2-one Derivatives as Ligands for α-Synuclein Fibrils.

Chu W, Zhou D, Gaba V, Liu J, Li S, Peng X, Xu J, Dhavale D, Bagchi DP, d'Avignon A, Shakerdge NB, Bacskai BJ, Tu Z, Kotzbauer PT, Mach RH.

J Med Chem. 2015 Aug 13;58(15):6002-17. doi: 10.1021/acs.jmedchem.5b00571. Epub 2015 Jul 31.


Sigma-2 receptor binding is decreased in female, but not male, APP/PS1 mice.

Sahlholm K, Liao F, Holtzman DM, Xu J, Mach RH.

Biochem Biophys Res Commun. 2015 May 1;460(2):439-45. doi: 10.1016/j.bbrc.2015.03.052. Epub 2015 Mar 18.


Supplemental Content

Support Center